Ropes & Gray advised IDRx on the deal. Clinical stage precision cancer biopharmaceutical company IDRx announced licensing transactions with Germany-based Merck KGaA and Blueprint Medicines to...
This content is for Standard 1 Year members only. LoginJoin Now